Scarica l'app Stockscreener
6.06
9.55%
-0.64
Dopo l'orario di chiusura:
6.20
0.14
+2.31%
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stock Holdings Lifted by JPMorgan Chase & Co. - Defense World
How to Take Advantage of moves in (JSPR) - Stock Traders Daily
Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $67.75 - Defense World
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Cantor Fitzgerald Forecasts JSPR FY2025 Earnings - Defense World
Research Analysts Set Expectations for JSPR FY2025 Earnings - MarketBeat
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Purchased by Barclays PLC - Defense World
Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Rises By 12.1% - Defense World
Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Grows By 12.1% - MarketBeat
HC Wainwright Cuts Jasper Therapeutics (NASDAQ:JSPR) Price Target to $40.00 - Defense World
What is HC Wainwright’s Forecast for JSPR Q1 Earnings? - Defense World
What is HC Wainwright's Estimate for JSPR Q1 Earnings? - MarketBeat
Jane Street Group LLC Takes $251,000 Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
What is HC Wainwright’s Estimate for JSPR FY2029 Earnings? - Defense World
Royal Bank of Canada Lowers Jasper Therapeutics (NASDAQ:JSPR) Price Target to $48.00 - Defense World
Jasper Therapeutics' SWOT analysis: briquilimab's potential in mast cell diseases - Investing.com India
Stock summary: Jasper Therapeutics witnessed loss overall loss of 67.19% throughout the week - Business Upturn
Jasper Therapeutics (NASDAQ:JSPR) Price Target Cut to $40.00 by Analysts at HC Wainwright - MarketBeat
What is HC Wainwright's Forecast for JSPR FY2029 Earnings? - MarketBeat
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) Announces Positive Preliminary Data from Jasper Therapeutics, Inc. BEACON Phase 1b/2a StudyOn January 8, 2025, Jasper Therapeutics, Inc. released a press release detailing encouraging preliminar - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Price Target Cut to $48.00 by Analysts at Royal Bank of Canada - MarketBeat
BMO maintains Jasper Therapeutics Outperform rating By Investing.com - Investing.com Australia
Why Jasper Therapeutics stock plunged 60% in one trading session - Dataconomy
Jasper Therapeutics' SWOT analysis: briquilimab's potential reshapes urticaria stock outlook - Investing.com India
Trading (JSPR) With Integrated Risk Controls - Stock Traders Daily
BTIG cuts Jasper Therapeutics price target to $64, maintains Buy By Investing.com - Investing.com Canada
Oppenheimer maintains $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Jasper’s Briquilimab Stands Up To Competition, But Investors Bail - News & Insights
BTIG cuts Jasper Therapeutics price target to $64, maintains Buy - Investing.com India
Buy rating upheld for Jasper Therapeutics stock as briquilimab progresses in trials - Investing.com Nigeria
Oppenheimer maintains $80 target on Jasper Therapeutics stock - Investing.com India
BMO maintains Jasper Therapeutics Outperform rating - Investing.com
Why Is Jasper Therapeutics Stock Trading Lower On Wednesday?Jasper Therapeutics (NASDAQ:JSPR) - Benzinga
Jasper Therapeutics stock dips following early trial results for chronic hives treatment - Investing.com Canada
Jasper Therapeutics stock tumbles after study data - Investing.com
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria - GlobeNewswire
Jasper's Briquilimab Achieves 100% Complete Response in Chronic Urticaria Trial Results - StockTitan
Jasper Therapeutics (NASDAQ:JSPR) Earns Market Outperform Rating from JMP Securities - Defense World
Jasper Therapeutics’ SWOT analysis: briquilimab’s potential reshapes urticaria stock outlook - Investing.com Nigeria
Jasper Therapeutics' SWOT analysis: briquilimab stock poised for growth in mast cell disease market - Investing.com Canada
Jasper Therapeutics’ SWOT analysis: briquilimab stock poised for growth in mast cell disease market - Investing.com Nigeria
Jasper Therapeutics (NASDAQ:JSPR) Receives "Market Outperform" Rating from JMP Securities - MarketBeat
Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025 - The Manila Times
Jasper Therapeutics to Host Webinar to Present Preliminary - GlobeNewswire
Jasper Therapeutics to Present Breakthrough CSU Treatment Data in January Webinar - StockTitan
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stock Position Lifted by Barclays PLC - Defense World
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Holdings Decreased by Geode Capital Management LLC - Defense World
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):